Introduction

Peptide selectivity describes the ability of a peptide to preferentially engage one receptor subtype over closely related family members. Many receptor families—such as the GLP-1 receptor family, the melanocortin receptors, and the somatostatin receptors—contain multiple subtypes with overlapping ligand specificity. Achieving selectivity is one of the central challenges in peptide drug design.

The Selectivity Challenge

Receptor subtypes within a family often share 60–80% sequence identity in their ligand-binding domains. This structural similarity means that endogenous peptides frequently bind multiple subtypes with comparable affinity. For example, α-MSH activates all five melanocortin receptor subtypes (MC1R–MC5R), producing diverse physiological effects ranging from pigmentation to appetite regulation.

From a pharmacological standpoint, activating the wrong subtype can produce adverse effects. Designing peptides that discriminate between subtypes requires exploiting the subtle structural differences that distinguish them.

Structural Basis of Selectivity

Binding Site Divergence

尽管 receptor subtypes share high overall homology, their binding pockets often contain non-conserved residues that can be exploited for selectivity. These divergent residues may differ in:

• Side chain volume: Larger residues in one subtype can exclude bulkier peptide analogs
• Charge distribution: Non-conserved charged residues create subtype-specific electrostatic environments
• Hydrophobicity: Differences in hydrophobic pocket depth and composition affect peptide binding mode

For example, the GLP-1 receptor and GLP-2 receptor share approximately 50% sequence identity in their extracellular domains but differ at several key positions in the transmembrane binding pocket. These differences have been exploited to design GLP-1R-selective agonists that do not cross-activate GLP-2R.

Allosteric Mechanisms

Some peptides achieve selectivity through allosteric mechanisms, binding to sites distant from the orthosteric pocket where endogenous ligands engage. Allosteric sites are typically less conserved across receptor subtypes, providing a larger structural basis for discrimination.

Positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) can modulate receptor subtype selectivity by altering the conformational landscape of the receptor.

Strategies for Engineering Selectivity

Amino Acid Substitution Scanning

Systematic substitution of individual amino acids with alanine or non-natural analogs reveals which positions contribute most to subtype discrimination. Residues that, when modified, dramatically alter the selectivity profile become primary targets for optimization.

Cyclization and Conformational Constraint

Cyclization restricts peptide conformational flexibility, reducing the number of conformers available for receptor binding. If one receptor subtype requires a specific conformation for high-affinity binding, constraining the peptide to that conformation can enhance selectivity.

Common cyclization strategies include:

• Disulfide bridges (e.g., oxytocin, somatostatin analogs)
• Lactam bridges (e.g., GLP-1 analogs)
• Side-chain-to-side-chain stapling
• Terminal-to-side-chain cyclization

Non-Natural Amino Acids

Incorporation of D-amino acids, β-amino acids, or other non-natural building blocks can introduce steric or electronic features that are tolerated by one subtype but not another. N-methylation of backbone amides is a particularly effective strategy for modulating selectivity.

Case Studies in Selectivity

Melanocortin Receptor Selectivity

The melanocortin system illustrates the selectivity challenge. α-MSH binds MC1R–MC5R with nanomolar affinity. Therapeutic applications require subtype selectivity:

• MC1R agonism: Pigmentation and photoprotection (afamelanotide)
• MC4R agonism: Appetite regulation and obesity (setmelanotide)
• MC3R antagonism: Metabolic benefits without cardiovascular effects

Melanotan II and its derivatives (PT-141, afmelanotide) demonstrate how structural modifications can shift selectivity profiles. Afamelanotide shows approximately 10-fold selectivity for MC1R over MC4R, while setmelanotide exhibits >100-fold selectivity for MC4R.

Somatostatin Receptor Subtypes

Five somatostatin receptor subtypes (SSTR1–SSTR5) are targets for neuroendocrine tumor therapy. Octreotide and lanreotide preferentially bind SSTR2, while pasireotide shows broader affinity with particularly high SSTR5 binding. The clinical profiles of these peptides differ substantially based on their receptor selectivity.

GLP-1 Receptor Family

The GLP-1 receptor family includes GLP-1R, GLP-2R, GIPR, and the glucagon receptor. Tirzepatide achieves dual GLP-1R/GIPR agonism through careful structural design, while semaglutide is highly GLP-1R selective. Understanding the molecular determinants of selectivity within this family has enabled rational design of multi-agonist peptides.

Selectivity Assessment Methods

Binding Assays

Radioligand competition assays across receptor subtypes provide equilibrium selectivity ratios. These are typically expressed as fold-difference in IC50 or Kd values between the target subtype and off-target subtypes.

Functional Assays

Binding selectivity does not always translate to functional selectivity. A peptide may bind two subtypes with similar affinity but produce different efficacies. Functional assays measuring second messenger responses (cAMP, calcium, β-arrestin recruitment) are essential for characterizing functional selectivity.

In Vivo Selectivity

In vivo selectivity is influenced by receptor expression patterns, tissue distribution, and pharmacokinetic factors. A peptide that appears non-selective in vitro may achieve functional selectivity in vivo due to differential receptor density in target versus off-target tissues.

Clinical Implications

Peptide selectivity directly impacts therapeutic index. Non-selective peptides often produce more side effects due to activation of unintended receptor subtypes. However, some clinical applications benefit from multi-receptor engagement, as seen with dual GLP-1R/GIPR agonists for obesity.

The ideal selectivity profile depends on the therapeutic context: complete selectivity may be desirable for avoiding toxicity, while moderate selectivity with some cross-reactivity may be acceptable or even beneficial for certain indications.